WO2002074257A2 - Selbstschäumende oder schaumförmige zubereitungen organischer hydrokolloiden - Google Patents

Selbstschäumende oder schaumförmige zubereitungen organischer hydrokolloiden Download PDF

Info

Publication number
WO2002074257A2
WO2002074257A2 PCT/EP2002/002853 EP0202853W WO02074257A2 WO 2002074257 A2 WO2002074257 A2 WO 2002074257A2 EP 0202853 W EP0202853 W EP 0202853W WO 02074257 A2 WO02074257 A2 WO 02074257A2
Authority
WO
WIPO (PCT)
Prior art keywords
group
acid
emulsifier
weight
cosmetic
Prior art date
Application number
PCT/EP2002/002853
Other languages
German (de)
English (en)
French (fr)
Other versions
WO2002074257A3 (de
Inventor
Andreas Bleckmann
Rainer Kröpke
Heidi Riedel
Original Assignee
Beiersdorf Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beiersdorf Ag filed Critical Beiersdorf Ag
Priority to US10/469,698 priority Critical patent/US20040142006A1/en
Priority to JP2002572968A priority patent/JP2004519498A/ja
Priority to EP02726173A priority patent/EP1370215A2/de
Publication of WO2002074257A2 publication Critical patent/WO2002074257A2/de
Publication of WO2002074257A3 publication Critical patent/WO2002074257A3/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36Carboxylic acids; Salts or anhydrides thereof
    • A61K8/361Carboxylic acids having more than seven carbon atoms in an unbroken chain; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/02Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04Dispersions; Emulsions
    • A61K8/046Aerosols; Foams
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34Alcohols
    • A61K8/342Alcohols having more than seven atoms in an unbroken chain
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/39Derivatives containing from 2 to 10 oxyalkylene groups
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q1/00Make-up preparations; Body powders; Preparations for removing make-up
    • A61Q1/02Preparations containing skin colorants, e.g. pigments
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/04Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations

Definitions

  • the present invention relates to self-foaming and / or foam-like cosmetic and dermatological preparations, in particular skin-care cosmetic and dermatological preparations.
  • Foams or foam-like preparations belong to the disperse systems.
  • Emulsions are two- or multi-phase systems of two or more liquids that are insoluble or only slightly soluble in one another.
  • the liquids pure or as solutions
  • the liquids are present in an emulsion in a more or less fine distribution, which is generally only of limited stability.
  • Foams are structures made of gas-filled, spherical or polyhedral cells, which are delimited by liquid, semi-liquid, highly viscous or solid cell bridges.
  • the cell bridges connected via so-called nodes, form a coherent framework.
  • the foam lamellae (closed-cell foam) stretch between the cell bars. If the foam lamellae are destroyed or flow back into the cell webs at the end of foam formation, an open-cell foam is obtained.
  • Foams are also thermodynamically unstable, since surface energy can be obtained by reducing the surface. The stability and therefore the existence of a foam depends on the extent to which it can prevent its self-destruction.
  • Cosmetic foams are generally dispersed systems composed of liquids and gases, the liquid being the dispersant and the gas being the dispersed substance. Foams made from low-viscosity liquids are temporarily stabilized by surface-active substances (surfactants, foam stabilizers). Because of their large inner surface, such surfactant foams have a strong adsorption capacity, which is used, for example, in cleaning and washing processes. Accordingly, cosmetic foams are used in particular in the areas of cleaning, for example as shaving cream, and hair care.
  • surfactants foam stabilizers
  • foam gas is blown into suitable liquids, or foam formation is achieved by vigorous beating, shaking, spraying or stirring the liquid in the gas atmosphere in question, provided that the liquids contain suitable surfactants or other surface-active substances (so-called foaming agents) that besides interfacial activity also possess a certain film-forming ability.
  • suitable surfactants or other surface-active substances so-called foaming agents
  • Cosmetic foams have the advantage over other cosmetic preparations in that they allow a fine distribution of active ingredients on the skin.
  • cosmetic foams can generally only be achieved by using special surfactants, which moreover are often not very kind to the skin.
  • Post-foaming preparations are often in special embodiments such as post-foaming shaving gels or the like.
  • German Offenlegungsschrift DE 197 54 659 discloses that carbon dioxide is a suitable active ingredient for stabilizing or increasing the epidermal ceramide synthesis rate, which can serve to strengthen the permeability barrier, reduce the transepidermal water loss and increase the relative skin moisture.
  • the CO 2 is dissolved in water, for example, with which the skin is then rinsed.
  • the state of the art has hitherto known no cosmetic or dermatological bases into which a gaseous active ingredient could be incorporated in sufficient, ie effective, concentration.
  • Another object of the present invention was therefore to find cosmetic or dermatological bases in which effective amounts of gaseous active ingredients can be incorporated.
  • At least one emulsifier A selected from the group of fully, partially or unneutralized, branched and / or unbranched, saturated and / or unsaturated fatty acids with a chain length of 10 to 40 carbon atoms.
  • At least one emulsifier B selected from the group of polyethoxylated fatty acid esters with a chain length of 10 to 40 carbon atoms and with a degree of ethoxylation of 5 to 100 and
  • At least one co-emulsifier C selected from the group consisting of saturated 10 and / or unsaturated, branched and / or unbranched fatty alcohols with a chain length of 10 to 40 carbon atoms,
  • foam-like cosmetic emulsions which are distinguished by a high air intake cannot be formulated without propellant gas
  • “self-foaming” or “foam-like” is to be understood to mean that the gas bubbles (as desired) are present in one (or more) liquid phase (s), the preparations not necessarily macroscopically
  • Self-foaming and / or foam-like cosmetic or dermatological preparations according to the invention can, for. B. represent macroscopically visible dispersed systems from gases dispersed in liquids.
  • the foam character can, for example, only become visible under a (light) microscope.
  • self-foaming according to the invention can, for. B. represent macroscopically visible dispersed systems from gases dispersed in liquids.
  • the foam character can, for example, only become visible under a (light) microscope.
  • the preparations according to the invention represent extremely satisfactory preparations in every respect. It was particularly surprising that the foam-like preparations according to the invention are extremely stable - even with an unusually high gas volume. Accordingly, they are particularly suitable to serve as the basis for forms of preparation with a variety of uses.
  • the preparations according to the invention show very good sensory properties, such as, for example, the distributability on the skin or the ability to be absorbed into the skin, and are furthermore distinguished by above-average skin care.
  • the subject of the invention is furthermore the use of self-foaming and / or foam-like cosmetic or dermatological preparations, which I. an emulsifier system, which from
  • At least one emulsifier A selected from the group of fully, partially or not neutralized, branched and / or unbranched, saturated and / or unsaturated fatty acids with a chain length of 10 to 40 carbon atoms,
  • At least one emulsifier B selected from the group of polyethoxylated fatty acid esters with a chain length of 10 to 40 carbon atoms and with a degree of ethoxylation of 5 to 100 and
  • At least one co-emulsifier C selected from the group consisting of saturated and / or unsaturated, branched and / or unbranched fatty alcohols with a chain length of 10 to 40 carbon atoms, and II. Up to 30% by weight of a lipid phase, based on the Total weight of preparation IV. Containing one or more substances selected from the group of organic hydrocolloids as a cosmetic or dermatological basis for gaseous active substances.
  • the one or more emulsifiers A are preferably selected from the group of fatty acids which are wholly or partly neutral with customary alkalis (such as sodium and / or potassium hydroxide, sodium and / or potassium carbonate and mono- and / or triethanolamine). are realized.
  • customary alkalis such as sodium and / or potassium hydroxide, sodium and / or potassium carbonate and mono- and / or triethanolamine.
  • stearic acid and stearates, isostearic acid and isostearates, palmitic acid and palmitates, and myristic acid and myristates are particularly advantageous.
  • the emulsifier (s) B are preferably selected from the following group: PEG-9 stearate, PEG-8 distearate, PEG-20 stearate, PEG-8 stearate, PEG-8 oleate, PEG-25 glyceryl trioleate, PEG- 40-sorbitan lanolate, PEG-15 glyceryl ricinoleate, PEG-20 glyceryl stearate, PEG-20 glyceryl isostearate, PEG-20 glyceryl oleate, PEG-20 stearate, PEG-20 methylglucose sesquistearate, PEG-30 glyceryl isostearate, PEG glyceryl, PEG-30 stearate, PEG-30 glyceryl stearate, PEG-40 stearate, PEG-30 glyceryl laurate, PEG-50 stearate, PEG-100 stearate, PEG-150 laurate.
  • the co-emulsifier (s) C are preferably selected from the following group: butyl octanol, butyl decanol, hexyl octanol, hexyl decanol, octyl decanol, behenyl alcohol (C 22 H 45 OH), cetearyl alcohol [a mixture of cetyl alcohol (C 16 H 33 OH) and stearyl alcohol (C 18 H 37 OH)], lanolin alcohols (wool wax alcohols, which represent the unsaponifiable alcohol fraction of the wool wax that is obtained after the saponification of wolf wax). Cetyl and cetylstearyl alcohol are particularly preferred.
  • weight ratios of emulsifier A to emulsifier B to coemulsifier C (A: B: C) as a: b: c, where a, b and c independently of one another are rational numbers from 1 to 5, preferably from 1 can represent up to 3.
  • a weight ratio of approximately 1: 1: 1 is particularly preferred.
  • the total amount of emulsifiers A and B and of coemulsifier C is advantageous for the total amount of emulsifiers A and B and of coemulsifier C to be in the range from 2 to 20% by weight, advantageously from 5 to 15% by weight, in particular from 8 to 13% by weight. %, each based on the total weight of the formulation.
  • the gas phase of the preparations contains carbon dioxide or consists entirely of carbon dioxide. It is especially advantageous if carbon dioxide constitutes one or the active ingredient in the preparations erfindungsgemä- SEN '.
  • compositions according to the invention develop into fine-bubble foams already during their production - for example during stirring or during homogenization.
  • fine-bubble, rich foams of excellent cosmetic elegance are available.
  • preparations which are particularly well tolerated by the skin are available according to the invention, and valuable ingredients can be distributed particularly well on the skin.
  • the formulations according to the present invention contain further emulsifiers. Those emulsifiers which are suitable for producing W / O emulsions are preferably to be used, these being able to be present both individually and in any combination with one another.
  • the other emulsifier (s) are advantageously selected from the group comprising the following compounds:
  • sorbitan stearate PEG-7 hydrogenated castor oil, PEG-5 soy sterol, PEG-6 sorbitan beeswax, glyceryl stearate , PEG-10 Hydrogenated Castor Oil, Sorbita npalmitate, PEG-22 / dodecyl glycol copolymer, polyglyceryl-2-PEG-4 stearate, sorbitan laurate, PEG-4 laurate, polysorbate 61, polysorbate 81, polysorbate 65, polysorbate 80, triceteareth-4-phosphate, triceteareth-4 phosphates and Sodium C 14 .
  • 17 alkyl see sulfonate (Hostacerin CG from Hoechst), glyceryl stearate and PEG-100 stearate (Arlacel 165 from ICI), polysorbate 85, trilaureth-4-phosphate, PEG-35 castor oil, sucrose stearate, trioleth-8-phosphate, C 12 .
  • the further emulsifier or emulsifiers are preferably selected from the group of the hydrophilic emulsifiers. According to the invention, particular preference is given to mono-, di-, trifatty acid esters of sorbitol.
  • the total amount of the further emulsifiers is advantageously chosen to be less than 5% by weight, based on the total weight of the formulation.
  • Particularly advantageous self-foaming and / or foam-like preparations in the sense of the present invention are free of mono- or diglyceryl fatty acid esters.
  • Preparations according to the invention which contain no glyceryl stearate, glyceryl isostearate, glyceryl diisostearate, glyceryl oleate, glyceryl palmitate, glyceryl myristate, glyceryl alcoholate and / or glyceryl laurate are particularly preferred.
  • the oil phase of the preparations according to the invention is advantageously selected from the group of nonpolar lipids with a polarity> 30 mN / m.
  • Particularly advantageous nonpolar lipids for the purposes of the present invention are those listed below.
  • paraffin oil in particular and further hydrogenated polyolefins such as hydrogenated polyisobutenes, squalane and squalene are to be used advantageously for the purposes of the present invention.
  • the content of the lipid phase is advantageously chosen to be less than 30% by weight, preferably between 2.5 and 30% by weight, particularly preferably between 5 and 15% by weight, in each case based on the total weight of the preparation.
  • the lipid phase contains up to 40% by weight, based on the total weight of the lipid phase, of polar lipids (with a polarity ⁇ 20 mN / m) and / or medium-polar lipids (with a polarity) from 20 to 30 mN / m) contains.
  • Particularly advantageous polar lipids for the purposes of the present invention are all na- ven 'lipids such.
  • medium-polar lipids for the purposes of the present invention are those listed below.
  • Hydrocolloid is the technological short name for the more correct term “hydrophilic colloid”. Hydrocolloids are macromolecules that are largely linear in shape and have intermolecular interaction forces that enable secondary and main valence bonds between the individual molecules and thus the formation of a network-like structure. They are partially water-soluble natural or synthetic polymers that form gels or viscous solutions in aqueous systems. They increase the viscosity of the water by either binding water molecules (hydration) or by absorbing and enveloping the water in their intertwined macromolecules, while at the same time restricting the mobility of the water.
  • Such water-soluble polymers represent a large group of chemically very different natural and synthetic polymers, the common feature of which is their solubility in water or aqueous media. The prerequisite for this is that these polymers have a sufficient number of hydrophilic groups for water solubility and are not too strongly crosslinked.
  • the hydrophilic groups can be nonionic, anionic or cationic in nature, for example as follows: +
  • the group of cosmetically and dermatologically relevant hydrocolloids can be divided as follows:
  • organic, natural compounds such as agar agar, carrageenan, tragacanth, gum arabic, alginates, pectins, polyoses, guar flour, locust bean gum, starch, dextrins, gelatin, casein,
  • organic, modified natural substances such as B. carboxymethyl cellulose and other cellulose ethers, hydroxyethyl and propyl cellulose and microcrystalline cellulose, the like,
  • organic, fully synthetic compounds such as.
  • inorganic compounds such as. B. polysilicic acids, clay minerals such as Montmoril- lonite, zeolites, silicas.
  • Microcrystalline cellulose is an advantageous hydrocolloid for the purposes of the present invention. It is available, for example, from the "FMC Corporation Food and Pharmaceutical Products” under the trade name Avicel®.
  • Avicel® A particularly advantageous product according to the present invention, the type Avicel® RC-591, which is a modified microcrystalline cellulose to 89% of microcrystalline cellulose and 11% to be: Removing sodium carboxymethyl cellulose composed.
  • Further Commercial products in this raw material class are Avicel® RC / CL, Avicel® CE-15, Avicel® 500.
  • hydrocolloids which are advantageous according to the invention are, for example, methyl celluloses, as the methyl ethers of cellulose are referred to. They are characterized by the following structural formula
  • R can represent a hydrogen or a methyl group.
  • cellulose mixed ethers which are generally also referred to as methyl celluloses and which, in addition to a dominant content of methyl, additionally contain 2-hydroxyethyl, 2-hydroxypropyl or 2-hydroxybutyl groups.
  • (Hydroxypropyl) methyl celluloses are particularly preferred, for example those sold under the trade name Methocel® E4M by Dow Chemical Comp. available.
  • sodium carboxymethyl cellulose the sodium salt of the glycolic acid ether of cellulose, for which R in structural formula I can be a hydrogen and / or CH 2 COONa.
  • R in structural formula I can be a hydrogen and / or CH 2 COONa.
  • Particularly preferred are the sodium carboxymethyl cellulose available under the trade name Natrosol Plus 330 CS from Aqualon, also referred to as cellulose gum.
  • xanthan (CAS No. 11138-66-2), also called xanthan gum, which is an anionic heteropolysaccharide which is generally formed from corn sugar by fermentation and is isolated as the potassium salt. It is produced by Xanthomonas campestris and some other species under aerobic conditions with a molecular weight of 2 * 10 6 to 24 * 10 6 .
  • Xanthan is formed from a chain with ß-1, 4-bound glucose (cellulose) with side chains. The structure of the subgroups consists of glucose, mannose, glucuronic acid, acetate and Pyruvate.
  • Xanthan is the name for the first microbial anionic heteropolysaccharide.
  • Xanthan is formed from a chain with ß-1, 4-bound glucose (cellulose) with side chains.
  • the subgroup structure consists of glucose, mannose, glucuronic acid, acetate and pyruvate. The number of pyruvate units determines the viscosity of the xanthane.
  • Xanthan is produced in two-day batch cultures with a yield of 70-90%, based on the carbohydrate used. Yields of 25-30 g / l are achieved. The work-up takes place after killing the culture by precipitation with z.
  • B. 2-propanol. Xanthan is then dried and ground.
  • An advantageous gelling agent in the sense of the present invention is also carrageenan, a gel-forming extract similar to agar, made from North Atlantic red algae (Chondrus crispus and Gigartina stellata), which is one of the florides.
  • carrageen is often used for the dried algae product and carrageenan for the extract from it.
  • the carrageenan precipitated from the hot water extract of the algae is a colorless to sand-colored powder with a molecular weight range of 100,000-800,000 and a sulfate content of approx. 25%.
  • Carrageenan which is very easily soluble in warm water; a thixotropic gel forms on cooling, even if the water content is 95-98%. The firmness of the gel is brought about by the double helix structure of the carrageenan.
  • the gel-forming K fraction consists of D-galactose-4-sulfate and 3,6-anhydro- ⁇ -D-galactose, which are alternately glycosidically linked in the 1,3 and 1,4 positions (In contrast, agar contains 3,6-anhydro- ⁇ -L-galactose).
  • the non-gelling ⁇ fraction is composed of 1,3-glycosidically linked D-galactose-2-sulfate and 1,4-linked D-galactose-2,6-disulfate residues and the like. Easily soluble in cold water.
  • the i-carrageenan composed of D-galactose-4-sulfate in 1,3-bond and 3,6-anhydro- ⁇ -D-galactose-2-sulfate in 1,4-bond is both water-soluble and gel-forming.
  • Other types of carrageenan are also designated with Greek letters: ⁇ , ß, ⁇ , ⁇ , v, ⁇ , ⁇ , ⁇ , ⁇ .
  • the type of cations present K + , NH 4 + , Na + , Mg 2+ , Ca 2+ ) also influences the solubility of the carrageenans.
  • the use of chitosan in cosmetic preparations is known per se. Chitossan is a partially deacylated chitin.
  • this biopolymer has film-forming properties and is characterized by a silky feeling on the skin.
  • a disadvantage is its strong stickiness on the skin, which occurs in particular - temporarily - during use. Appropriate preparations may then not be marketable in individual cases because they are not accepted by consumers or judged negatively.
  • Chitosan is known to be used, for example, in hair care. It is better than the chitin on which it is based as a thickener or stabilizer and improves the adhesion and water resistance of polymer films. Representing a large number of prior art sources: HPFiedler, "Lexicon of auxiliary substances for pharmacy, cosmetics and related areas", third edition 1989, Editio Cantor, Aulendorf, p. 293, keyword "Chitosan”.
  • n assumes values up to approx. 10,000
  • X represents either the acetyl radical or hydrogen.
  • Chitosan is formed by deacetylation and partial depolymerization (hydrolysis) of chitin, which is due to the structural formula
  • arthropods e.g. insects, crabs, spiders
  • supporting tissues of other organisms e.g. molluscs, algae, fungi.
  • chitosan In the range of approximately pH ⁇ 6, chitosan is positively charged and is also soluble there in aqueous systems. It is not compatible with anionic raw materials. Therefore, the use of nonionic emulsifiers is suitable for the production of chitosan-containing oil-in-water emulsions. These are known per se, for example from EP-A 776 657.
  • Chitosans with a degree of deacetylation> 25%, in particular> 55 to 99% [determined by means of 1 H-NMR] are preferred according to the invention.
  • chitosans with molecular weights between 10,000 and 1,000,000, especially those with molecular weights between 100,000 and 1,000,000. [determined by gel permeation chromatography].
  • Polyacrylates are also advantageous gelators to be used in the sense of the present invention.
  • Polyacrylates which are advantageous according to the invention are acrylate-alkyl acrylate copolymers, in particular those selected from the group of the so-called carbomers or carbopols (Carbopol® is actually a registered trademark of the B.F. Goodrich Company).
  • the acrylate-alkyl acrylate copolymers which are advantageous according to the invention are distinguished by the following structure:
  • R ' represents a long-chain alkyl radical and x and y numbers which symbolize the respective stoichiometric proportion of the respective comonomers.
  • acrylate copolymers and / or acrylate-alkyl-acrylate copolymers which are available from the BFGoodrich Company under the trade names Carbopol® 1382, Carbopol® 981 and Carbopol® 5984, preferably polyacrylates from the group of carbopoles of types 980 , 981, 1382, 2984, 5984 and particularly preferably Carbomer 2001
  • ammonium acryloyldimethyltaurate / vinylpyrrolidone copolymers have the empirical formula [C 7 H 16 N 2 S0 4 ] n [C 6 H 9 NO] m , corresponding to a statistical structure as follows
  • water-soluble or dispersible anionic polyurethanes which are advantageously obtainable from i) at least one compound which contains two or more active hydrogen atoms per molecule, 10 ii) at least one diol containing acid or salt groups and iii) at least one diisocyanate.
  • Component i) is in particular diols, amino alcohols, diamines,
  • polyesterols polyetherols with a number average molecular weight of up to 3000 each, or mixtures thereof, it being possible for up to 3 mol% of the compounds mentioned to be replaced by triols or triamines.
  • Diols and polyester diols are preferred.
  • component (a) comprises at least 50% by weight, based on the total weight of component (a), of a polyester diol.
  • polyester diols all those
  • nigen which are usually used for the production of polyurethanes, in particular reaction products of phthalic acid and diethylene glycol, isophthalic acid and 1,4-butanediol, isophthalic acid / adipic acid and 1,6-hexanediol and adipic acid and ethylene glycol or 5- NaS0 3 -sophthalic acid, phthalic acid, adipic acid and 1, 6-hexanediol.
  • Useful diols are e.g. Ethylene glycol, propylene glycol, butylene glycol, neopentyl glycol, polyetherols, such as polyethylene glycols with molecular weights up to 3000, block copolymers of ethylene oxide and propylene oxide with number average molecular weights of up to 3000 or block copolymers of ethylene oxide, propylene oxide and Bu-
  • tylene oxide which contain the alkylene oxide units randomly distributed or polymerized in the form of blocks.
  • Ethylene glycol, neopentyl glycol, di-, tri-, tetra-, penta or hexaethylene glycol are preferred.
  • Diols which can also be used are poly ( ⁇ -hydroxycarboxylic acid) diols.
  • Suitable amino alcohols are, for example, 2-aminoethanol, 2- (N-methylamino) ethanol, 3-aminopropanol or 4-aminobutanol.
  • Suitable diamines are e.g. Ethylene diamine, propylene diamine, 1, 4-diaminobutane and 1, 6-diaminohexane and ⁇ , ⁇ -diamines, which can be prepared by amination of polyalkylene oxides with ammonia.
  • Component ii) is in particular dimethylolpropanoic acid or compounds of the formulas
  • RR stands for a C 2 -C 18 alkylene group and Me stands for Na or K.
  • Component iii) is in particular hexamethylene diisocyanate, isophorone diisocyanate, methyl diphenyl isocyanate (MDI) and / or tolylene diisocyanate.
  • the polyurethanes are obtainable by reacting the compounds of groups i) and ii) with the compounds of group iii) under an inert gas atmosphere in an inert solvent at temperatures from 70 to 130 ° C. This reaction can optionally be carried out in the presence of chain extenders in order to produce polyurethanes with higher molecular weights.
  • the components [(i) + (ii)]: iü) are advantageously used in a molar ratio of 0.8 to 1, 1: 1 used.
  • the acid number of the polyurethanes is determined by the composition and the concentration of the compounds of component (ii) in the mixture of components (i) + (ii).
  • the H. Fikentscher K values (determined in 0.1% by weight solutions in N-methylpyrrolidone at 25 ° C. and pH 7) of 15 to 100, preferably 25 to 50.
  • the polyurethanes containing acid groups are (partially or completely) water-soluble or dispersible without the aid of emulsifiers.
  • the salts of the polyurethanes generally have better water solubility or dispersibility in water than the non-neuralized polyurethanes.
  • Alkali metal bases such as sodium hydroxide solution, potassium hydroxide solution, sodium carbonate, sodium hydrogen carbonate, potassium carbonate or potassium hydrogen carbonate and alkaline earth metal bases such as calcium hydroxide, calcium oxide, magnesium hydroxide or magnesium carbonate as well as ammonia and amines can be used as the base for the neutralization of the polyurethanes.
  • 2-Amino-2-methylpropanol, diethylaminopropylamine and triisopropanolamine have proven particularly useful for neutralizing the polyurethanes containing acid groups.
  • the neutral tion of the polyurethanes containing acid groups can also be carried out with the aid of mixtures of several bases, for example mixtures of sodium hydroxide solution and triisopropanolamine.
  • the neutralization can be partial, for example 20 to 40% or complete, ie 100%.
  • Water-soluble or dispersible, cationic polyurethanes and polyureas from " a) at least one diisocyanate, which may have previously been reacted with one or more compounds which contain two or more active hydrogen atoms per molecule, and b) at least one diol , primary or secondary amino alcohol, primary or secondary diamine or primary or secondary triamine with one or more tertiary, quaternary or protonated tertiary amino nitrogen atoms.
  • Preferred diisocyanates are as indicated under 1) above.
  • Compounds with two or more active hydrogen atoms are diols, amino alcohols, diamines, polyesterols.
  • Polyamide diamines and polyetherols. Suitable compounds of this type are indicated as under 1) above.
  • the polyurethanes are produced as described under 1) above.
  • Charged cationic groups can be generated from the tertiary amino nitrogen atoms present either by pretonation, for example with carboxylic acids such as lactic acid, or by quaternization, for example with alkylating agents such as C to C 4 alkyl halides or sulfates in the polyureas.
  • alkylating agents such as C to C 4 alkyl halides or sulfates in the polyureas. Examples of such alkylating agents are ethyl chloride, ethyl bromide, methyl chloride, methyl bromide, dimethyl sulfate and diethyl sulfate.
  • Linear polyurethanes with carboxylate groups from i) a 2,2-hydroxymethyl-substituted carboxylic acid of the formula
  • RR ' represents a hydrogen atom or a C 1 -C 2 -alkyl group which is used in an amount which is sufficient for 0.35 to 2.25 in the polyurethane
  • Milliequivalents of carboxyl groups are present per g of polyurethane
  • carboxyl groups contained in the polyurethane are at least partially neutralized with a suitable base.
  • Carboxyl-containing polycondensation products from anhydrides of tri- or tetracarboxylic acids and diols, diamines or amino alcohols (polyesters, polyamides or polyester amides). These polymers and their preparation are described in more detail in DE-A-42 24 761, to which reference is hereby made in full.
  • the polymers used according to the invention preferably have a K value of 25 to 100, preferably 25 to 50.
  • the polymers in the composition according to the invention are generally present in an amount in the range from 0.2 to 20% by weight on the total weight of the agent.
  • the salt is used in an amount effective to improve the interchangeability of the polymers. In general mine is used in an amount of 0.02 to 10 wt .-%, preferably 0.05 to 5 wt .-% and in particular 0.1 to 3 wt .-%, based on the total weight of the agent, the salt.
  • the total amount of one or more hydrocolloids in the finished cosmetic or dermatological preparations is advantageously less than 5% by weight, preferably between 0.1 and 1.0% by weight, based on the total weight of the preparations.
  • the 'inventive cosmetic and / or dermatological preparations can be composed as usual.
  • Preparations for skin care are particularly advantageous for the purposes of the present invention: they can be used for cosmetic and / or dermatological light protection, for treating the skin and / or hair and as a make-up product in decorative cosmetics.
  • a further advantageous embodiment of the present invention consists in after-sun products.
  • cosmetic or topical dermatological compositions can be used for the purposes of the present invention, for example as a skin protection cream, day or night cream, etc. It may be possible and advantageous to use the compositions according to the invention as the basis for pharmaceutical formulations.
  • the preparations according to the invention can also represent “cleaning foams” which are used, for example, to remove make-up and / or make-up or as a mild wash foam - if appropriate also for Such cleansing foams can advantageously also be used as so-called “rinse off” preparations, which are rinsed off the skin after use
  • the cosmetic and / or dermatological preparations according to the invention can also advantageously be in the form of a foam for the care of the hair or the scalp. lie, in particular a foam for inserting the hair, a foam that is used for blow-drying the hair, a hairdressing and treatment foam.
  • the cosmetic and dermatological preparations according to the invention are applied to the skin and / or the hair in a sufficient amount in the manner customary for cosmetics.
  • the cosmetic and dermatological preparations according to the invention can contain cosmetic auxiliaries, such as are usually used in such preparations, for.
  • cosmetic auxiliaries such as are usually used in such preparations, for.
  • preservation aids such as bactericides, perfumes, dyes, pigments that have a coloring effect, moisturizing and / or moisturizing substances, fillers that improve the feeling on the skin, fats, oils, waxes or other common components of a cosmetic or dermatological formulation
  • fillers that improve the feeling on the skin, fats, oils, waxes or other common components of a cosmetic or dermatological formulation such as alcohols , Polyols, polymers, foam stabilizers, electrolytes, organic solvents or silicone derivatives.
  • Advantageous preservatives for the purposes of the present invention are, for example, formaldehyde releasers (such as, for example, DMDM hydantoin), iodopropyl butyl carbamates (for example those available under the trade names Koncyl-L, Koncyl-S and Konkaben LMB from Lonza), parabens, Phenoxyethanol, ethanol, benzoic acid and the like.
  • the preservation system usually also advantageously comprises preservation aids, such as, for example, octoxyglycerol, glycine soya, etc.
  • compositions are also obtained if antioxidants are used as additives or active ingredients.
  • the preparations advantageously contain one or more antioxidants. All of the antioxidants suitable or customary for cosmetic and / or dermatological applications can be used as inexpensive, but nevertheless optional, antioxidants.
  • the antioxidants are advantageously selected from the group consisting of amino acids (e.g. glycine, histidine, tyrosine, tryptophan) and their derivatives, imidazoles (e.g. urocanic acid) and their derivatives, peptides such as D, L-carnosine, D-carnosine, L-camosine and their derivatives (e.g. anserine), carotenoids, carotenes (e.g. ⁇ -carotene, ß-carotene, lycopene) and their derivatives, lipoic acid and their derivatives (e.g.
  • amino acids e.g. glycine, histidine, tyrosine, tryptophan
  • imidazoles e.g. urocanic acid
  • peptides such as D, L-carnosine, D-carnosine, L-camosine and their derivatives (e.g. anserine)
  • carotenoids e.g
  • thiols e.g. thioredoxin, glutathione, cysteine, cystine, cystamine and their glycosyl, N-acetyl, methyl, ethyl, propyl, amyl, butyl and lauryl, palmitoyl, oleyl -, ⁇ -Linoleyl, cholesteryl and glyceryl esters
  • salts dilauryl thiodipropionate, distearyl thiodipropionate, thiodipropionic acid and their derivatives (esters, ethers, peptides, lipids, nucleotides, nucleosides and salts) as well as sulfoximine compounds (e.g.
  • buthioninsulfoxim Homocysteine sulfoximine, buthionine sulfones, penta-, hexa-, heptathionine sulfoximine) in very low tolerable doses e.g. pmol to ⁇ m ⁇ l / kg
  • also (metal) chelators e.g. ⁇ -hydroxy fatty acids, palmitic acid, phytic acid, Lactoferrin
  • ⁇ -hydroxy acids e.g.
  • citric acid citric acid, lactic acid, malic acid
  • hum Inic acid bile acid, bile extracts, bilirubin, biliverdin, EDTA, EGTA and their derivatives
  • unsaturated fatty acids and their derivatives e.g. B. ⁇ -linolenic acid, linoleic acid, oleic acid
  • folic acid and its derivatives ubiquinone and ubiquinol and their derivatives
  • vitamin C and derivatives e.g. ascorbyl palmitate, Mg - ascorbyl phosphate, ascorbyl acetate
  • tocopherols and derivatives e.g.
  • vitamin E - acetate vitamin A and derivatives (vitamin A - palmitate) as well as konyferyl benzoate of benzoin, rutinic acid and its derivatives, ferulic acid and its derivatives, butylhydroxytoluene, butylhydroxyanisole, nordihydroguajak resin acid, nordihydroguajaretic acid, trihydroxybutyrophenone and its derivatives, urine Derivatives, zinc and its derivatives (e.g. ZnO, ZnSO4) selenium and its derivatives (e.g. selenium methionine), stilbenes and their derivatives (e.g. stilbene oxide, trans-stilbene oxide) and the derivatives (salts, Esters, ethers, sugars, nucleotides, nucleosides, peptides and lipids) of these active ingredients.
  • konyferyl benzoate of benzoin, rutinic acid and its derivatives, ferulic acid and its derivatives, but
  • water-soluble antioxidants such as vitamins, e.g. B. ascorbic acid and its derivatives.
  • compositions according to the invention are very good vehicles for cosmetic or dermatological active ingredients in the skin, preferred active ingredients being antioxidants which can protect the skin against oxidative stress.
  • preferred active ingredients are vitamin E and its derivatives and vitamin A and its derivatives.
  • the amount of the antioxidants (one or more compounds) in the preparations is preferably 0.001 to 30% by weight, particularly preferably 0.05 to 20% by weight, in particular 0.1 to 10% by weight, based on the total weight the preparation.
  • vitamin E and / or its derivatives represent the antioxidant (s)
  • vitamin A or vitamin A derivatives or carotenes or their derivatives represent the antioxidant (s)
  • the active ingredients can also be selected very advantageously from the group of lipophilic active ingredients, in particular from the following group:
  • the active ingredient (s) are particularly advantageously selected from the group of NO synthase inhibitors, in particular if the preparations according to the invention are used for Treatment and prophylaxis of the symptoms of intrinsic and / or extrinsic aging of the skin and for the treatment and prophylaxis of the harmful effects of ultraviolet radiation on the skin are intended to serve.
  • the preferred NO synthase inhibitor is nitroarginine.
  • the active ingredient (s) are furthermore advantageously selected from the group comprising catechins and bile acid esters of catechins and aqueous or organic extracts from plants or parts of plants which contain catechins or bile acid esters of catechins, such as, for example, the leaves of the Theaceae plant family , especially the species Camellia sinensis (green tea).
  • catechins and bile acid esters of catechins and aqueous or organic extracts from plants or parts of plants which contain catechins or bile acid esters of catechins, such as, for example, the leaves of the Theaceae plant family , especially the species Camellia sinensis (green tea).
  • Their typical ingredients such as polyphenols or catechins, caffeine, vitamins, sugar, minerals, amino acids, lipids are particularly advantageous.
  • Catechins are a group of compounds which are to be regarded as hydrogenated flavones or anthocyanidins and derivatives of "catechins” (catechol, 3,3 ', 4', 5,7-flavanpentaol, 2- (3,4- Dihydroxyphenyl) -chroman-3,5,7-triol) Also epicatechin ((2R, 3R) -3,3 ', 4', 5,7-flavanpentaol) is an advantageous active substance in the sense of the present invention.
  • Plant extracts containing catechins in particular extracts of green tea, such as. B. extracts from leaves of the plants of the species Camellia spec, especially the teas Camellia sinenis, C. assamica, C. taliensis or C. irrawadiensis and crosses of these with, for example, Camellia japonica.
  • Preferred active ingredients are also polyphenols or catechins from the group (-) - catechol, (+) - catechin, (-) - catechin gallate, (-) - gallocatechin gallate, (+) - epicatechin, (-) - epicatechin , (-) - epicatechin gallate, (-) - epigallocatechin, (-) - epigallocatechin gallate.
  • Flavon and its derivatives are advantageous active substances in the sense of the present invention. They are characterized by the following basic structure (substitution positions specified):
  • flavones usually occur in glycosidated form.
  • the flavonoids are preferably chosen from the group of substances of the generic structural formula
  • Z, to Z 7 are selected independently of one another from the group H, OH, alkoxy and hydroxyalkoxy, where the alkoxy or hydroxyalkoxy groups can be branched and unbranched and can have 1 to 18 C atoms, and wherein Gly is selected from the group of mono- and oligoglycoside residues.
  • the flavonoids can also be advantageously selected from the group of substances of the generic structural formula
  • Z 1 to 18 carbon atoms may have from the group H, OH, alkoxy and hydroxyalkoxy, where the alkoxy and hydroxyalkoxy groups may be branched and unbranched and 'through Z 6 are selected independently of one another, and wherein Gly is chosen from the group of mono- and oligoglycoside residues.
  • Such structures can preferably be selected from the group of substances of the generic structural formula wherein Gly 1 t Gly 2 and Gly 3 independently of one another represent monoglycoside residues or. Gly 2 or Gly 3 can also individually or together represent saturations by hydrogen atoms.
  • Gly ⁇ Gly 2 and Gly 3 are preferably selected independently of one another from the group of the hexosyl residues, in particular the rhamnosyl residues and glucosyl residues.
  • hexosyl radicals for example allosyl, altrosyl, galactosyl, gulosyl, idosyl, mannosyl and talosyl, may also be used advantageously. It can also be advantageous according to the invention to use pentosyl residues.
  • Z to Z 5 are advantageously selected independently of one another from the group H, OH, methoxy, ethoxy and 2-hydroxyethoxy, and the flavone glycosides have the structure
  • Gly 1 ( Gly 2 and Gly 3 independently of one another represent monoglycoside residues or. Gly 2 or Gly 3 can also represent, individually or together, saturations by hydrogen atoms.
  • Gly, Gly 2 and Gly 3 are preferably selected independently of one another from the group of the hexosyl radicals, in particular the rhamnosyl radicals and glucosyl radicals.
  • hexosyl radicals for example allosyl, altrosyl, galactosyl, gulosyl, idosyl, mannosyl and talosyl, may also be used advantageously. It can also be advantageous according to the invention to use pentosyl residues.
  • flavone glycosides from the group ⁇ -glucosyl rutin, ⁇ -glucosyl myrcetin, ⁇ -glucosyl iso-quercitrin, ⁇ -glucosyl iso-quercetin and ⁇ -glucosyl-quercitrin.
  • ⁇ -glucosylrutin is particularly preferred.
  • naringin aurantiin, naringenin-7-rhamnoglucosid
  • hesperidin 3 ', 5,7-trihydroxy-4'-methoxyflavanon-7-rutinoside
  • hesperidoside hesperetin-7-O-rutinoside
  • Rutin (3,3 ', 4', 5,7-pentahydroxyflyvon-3-rutinoside, quercetin-3-rutinoside, sophorin, birutan, rutabion, taurutin, phytomelin, melin), troxerutin (3,5-dihydroxy-3 ', 4', 7-tris (2-hydroxyethoxy) flavon-3- (6-0- (6-deoxy- ⁇ -L-mannopyranosyl) -ß-D-glucopyranoside)), monoxerutin (3.3 ', 4', 5-tetrahydroxy-7- (2-hydroxyethoxy) flavon-3- (6-O- (6-deoxy- ⁇ -L-mannopyranosyl) -ß-D-glucopyranoside)), dihydrorobinetin ( 3,3 ', 4', 5 ', 7-pentahydroxyflavanone), taxifolin (3,3', 4 ', 5,7-pentahydroxyflavanone), er
  • the active ingredient (s) from the group of ubiquinones and plastoquinones.
  • Coenzyme Q10 which is characterized by the following structural formula, is particularly advantageous:
  • Creatine and / or creatine derivatives are also preferred active substances for the purposes of the present invention. Creatine is characterized by the following structure:
  • Preferred derivatives are creatine phosphate and creatine sulfate, creatine acetate, creatine ascorbate and the derivatives esterified on the carboxyl group with mono- or polyfunctional alcohols.
  • acyl-camitines which are selected from the group of substances of the following general structural formula
  • the list of the active substances or combinations of active substances mentioned which can be used in the preparations according to the invention is of course not intended to be limiting.
  • the active ingredients can be used individually or in any combination with one another.
  • Skin aging is e.g. B. caused by endogenous, genetically determined factors. In the epidermis and dermis it occurs due to aging e.g. B. the following structural damage and malfunctions, which may also fall under the term "senile xerosis":
  • Exogenous factors such as UV light and chemical pollutants
  • exogenous factors e.g. B. the following structural damage and functional disorders in the skin, which go beyond the extent and quality of the damage with chronological aging:
  • formulations according to the invention can also have an anti-wrinkle effect or considerably increase the effect of known anti-wrinkle active ingredients. Accordingly, formulations in the sense of the present invention are suitable fertilizing is particularly advantageous "for the prophylaxis and treatment of cosmetic or dermatological skin changes, such as those that occur during skin aging. They are also advantageous against the appearance of dry or rough skin.
  • the present invention therefore relates to products for the care of the naturally aged skin and for the treatment of the consequential damage caused by light aging, in particular the phenomena listed under a) to g).
  • the water phase of the preparations according to the invention can advantageously contain customary cosmetic auxiliaries, such as, for example, alcohols, in particular those having a low C number, preferably ethanol and / or isopropanol, diols or polyols having a low C number, and their ethers, preferably propylene glycol, glycerol, ethylene glycol, Ethylene glycol monoethyl or monobutyl ether, propylene glycol monomethyl, monoethyl or monobutyl ether, diethylene glycol monomethyl or monoethyl ether and analog products, polymers, foam stabilizers, electrolytes and moisturizers.
  • customary cosmetic auxiliaries such as, for example, alcohols, in particular those having a low C number, preferably ethanol and / or isopropanol, diols or polyols having a low C number, and their ethers, preferably propylene glycol, glycerol, ethylene glycol,
  • Moisturizers are substances or mixtures of substances that give cosmetic or dermatological preparations the property of reducing the release of moisture from the horny layer (also called trans-epidermal water loss (TEWL)) and / or hydrating the skin after application or distribution on the skin surface To influence the horny layer positively.
  • TEWL trans-epidermal water loss
  • moisturizers for the purposes of the present invention are, for example, glycerol, lactic acid, pyrrolidone carboxylic acid and urea. Furthermore, it is particularly advantageous to use polymeric moisturizers from the group of water-soluble and / or water-swellable and / or water-gelable polysaccharides. Particularly advantageous are, for example, hyaluronic acid, chitosan and / or a fucose-rich polysaccharide, which is filed in the Chemical Abstracts under the registration number 178463-23-5 and z. B. under the name Fucogel®1000 from the company SOLABIA S.A. is available.
  • the cosmetic and dermatological preparations according to the invention can contain dyes and / or color pigments, especially if they are in the form of decorative ratative cosmetics are available.
  • the dyes and pigments can choose from for the corresponding positive list of the Cosmetics Directive or the EC list of cosmetic colorants be selected. In most cases, they are identical to the colorants approved for food.
  • Advantageous color pigments are, for example, titanium dioxide, mica, iron oxides (for example Fe 2 O 3 , Fe 3 O 4 , FeO (OH)) and / or tin oxide.
  • Advantageous dyes are, for example, carmine, Berlin blue, chrome oxide green, ultramarine blue and / or manganese violet. It is particularly advantageous to choose the dyes and / or color pigments from the list below.
  • the Color Index Numbers (CIN) are taken from the f? O ⁇ ve Color Index, 3rd edition, Society of Dyers and Colo ⁇ sts, Bradford, England, 1971.
  • Chlorophyll a and b Copper compounds of chlorophyll and 75810 green
  • Chromium oxide containing 77289 green
  • Titanium dioxide and its mixtures with mica 77891 white
  • the formulations according to the invention are in the form of products which are used on the face, it is advantageous to choose one or more substances from the following group as the dye: 2,4-dihydroxyazobenzene, 1- (2'-chloro-4 , - nitro-1'-phenylazo) -2-hydroxynaphthalene, ceres red, 2- (sulfo-1-naphthylazo) -1-naphthol-4-sulfonic acid, calcium salt of 2-hydroxy-1, 2'-azonaphthalene-1'- sulfonic acid, calcium and barium salts of 1- (2-sulfo-4-methyl-1-phenylazo) -2-naphthylcarboxylic acid, calcium salt of 1- (2-sulfo-1-naphthylazo) -2-hydroxynaphthalene-3-carboxylic acid, aluminum salt 1- (4-sulfo-1-phenylazo) -2-naphthol-6-sulfonic acid
  • oil-soluble natural dyes such as. B. paprika extracts, ß-carotene or cochineal.
  • Formulations containing pearlescent pigments are also advantageous for the purposes of the present invention.
  • the types of pearlescent pigments listed below are particularly preferred:
  • Natural pearlescent pigments such as. B.
  • Monocrystalline pearlescent pigments such as B. Bismuth oxychloride (BiOCI)
  • Layer-substrate pigments e.g. B. mica / metal oxide
  • pearlescent pigments are, for example, powdery pigments or castor oil dispersions of bismuth oxychloride and / or titanium dioxide and bismuth oxychloride and / or titanium dioxide on mica. Particularly advantageous is z.
  • pearlescent pigment types based on mica / metal oxide are also advantageous:
  • pearlescent pigments available from Merck under the trade names Timiron, Colorona or Dichrona.
  • pearlescent pigments which are advantageous in the sense of the present invention are obtainable in numerous ways known per se.
  • other substrates besides mica can be coated with other metal oxides, such as. B. silica and the like.
  • metal oxides such as. B. silica and the like.
  • Ronaspheren Ti0 2 and Fe 2 0 3 coated SiO 2 particles
  • Iron pearlescent pigments which are produced without the use of mica are particularly preferred. Such pigments are e.g. B. available under the trade name Sicopearl copper 1000 from BASF.
  • effect pigments which are available from Flora Tech under the trade name Metasomes Standard / Glitter in various colors (yello, red, green, blue).
  • the glitter particles are present in mixtures with various auxiliaries and dyes (such as, for example, the dyes with the Color Index (Cl) numbers 19140, 77007, 77289, 77491).
  • the dyes and pigments can be present either individually or in a mixture and can be coated with one another, with different coatings being used. different thickness effects are generally caused.
  • the total amount of dyes and coloring pigments is advantageously from the range of z. B. 0.1% by weight to 30% by weight, preferably from 0.5 to 15% by weight, in particular from 1.0 to 10% by weight, in each case based on the total weight of the preparations ,
  • cosmetic and dermatological preparations the main purpose of which is not protection from sunlight, but which nevertheless contain UV protection substances.
  • So z. B. usually incorporated into day creams or makeup products UV-A or UV-B filter substances.
  • UV protection substances like antioxidants and, if desired, preservatives, also provide effective protection of the preparations themselves against spoilage.
  • Cosmetic and dermatological preparations which are in the form of a sunscreen are also favorable.
  • the preparations preferably contain, in addition to one or more UV filter substances according to the invention, at least one further UV-A and / or UV-B filter substance.
  • the formulations may, although not necessary, optionally also contain one or more organic and / or inorganic pigments as UV filter substances, which may be present in the water and / or the oil phase.
  • Preferred inorganic pigments are metal oxides and / or other metal compounds which are sparingly soluble or insoluble in water, in particular oxides of titanium (Ti0 2 ), zinc (ZnO), iron (e.g. Fe 2 0 3 ), zirconium (Zr0 2 ), silicon ( SiO 2 ), manganese (e.g. MnO), aluminum (Al 2 0 3 ), cerium (e.g. Ce 2 0 3 ), mixed oxides of the corresponding metals and mixtures of such oxides.
  • such pigments can advantageously be surface-treated (“coated”), with an amphiphilic or hydrophobic character, for example, being formed or retained.
  • This surface treatment can consist in that the pigments are coated with a thin film using methods known per se be provided with a hydrophobic layer.
  • Ti0 2 pigments coated with aluminum stearate eg. B. those available under the trade name MT 100 T from TAYCA.
  • Another advantageous coating of the inorganic pigments consists of dimethylpolysiloxane (also: dimethicone), a mixture of fully methylated, linear siloxane polymers, which are blocked at the end with trimethylsiloxy units.
  • Zinc oxide pigments which are coated in this way are particularly advantageous for the purposes of the present invention.
  • the inorganic pigments are also advantageous to coat with a mixture of dimethylpolysiloxane, in particular dimethylpolysiloxane with an average chain length of 200 to 350 dimethylsiloxane units, and silica gel, which is also referred to as simethicone. It is particularly advantageous if the inorganic pigments are additionally coated with aluminum hydroxide or aluminum oxide hydrate (also: alumina, CAS no .: 1333-84-2). Titanium dioxides coated with simethicone and alumina are particularly advantageous, the coating also being able to contain water. An example of this is the titanium dioxide available from Merck under the trade name Eusolex T2000.
  • An advantageous organic pigment for the purposes of the present invention is 2,2'-methylene-bis- (6- (2H-benzotriazol-2-yl) -4- (1,1,3,3-tetramethylbutyl) phenol) [INCI: bisoctyl-triazole], which is characterized by the chemical structural formula
  • Tinosorb® M is marked and is available under the trade name Tinosorb® M from CIBA-Chemical GmbH.
  • Preparations according to the invention advantageously contain substances which absorb UV radiation in the UV-A and / or UV-B range, the total amount of the filter substances, for. B. 0.1% by weight to 30% by weight, preferably 0.5 to 20% by weight, in particular 1.0 to 15.0% by weight, based on the total weight of the preparations, for cosmetic purposes
  • the total amount of the filter substances for. B. 0.1% by weight to 30% by weight, preferably 0.5 to 20% by weight, in particular 1.0 to 15.0% by weight, based on the total weight of the preparations, for cosmetic purposes
  • UV-A filter substances for the purposes of the present invention are dibenzoyl methane derivatives, in particular 4- (tert-butyl) -4'-methoxydibenzoyl methane (CAS No. 70356-09-1), which is available from Givaudan under the Parsol brand ® 1789 and is sold by Merck under the trade name Eusolex® 9020.
  • dibenzoyl methane derivatives in particular 4- (tert-butyl) -4'-methoxydibenzoyl methane (CAS No. 70356-09-1), which is available from Givaudan under the Parsol brand ® 1789 and is sold by Merck under the trade name Eusolex® 9020.
  • UV-A filter substances are phenylene-1,4-bis (2-benzimidazyl) -3,3'-5,5'-tetrasulfonic acid
  • salts especially the corresponding sodium, potassium or triethanolammonium salts, in particular the phenylene-1,4-bis (2-benzimidazyl) -3,3'-5,5'-tetrasulfonic acid-bis sodium salt
  • 1,4-di (2-oxo-10-sulfo-3-bornylidenemethyl) benzene and its salts especially the corresponding 10-sulfato compounds, especially the corresponding sodium, potassium or triethanolammonium salt
  • benzene-1,4-di (2-oxo-3-bornylidenemethyl-10-sulfonic acid is also called benzene-1,4-di (2-oxo-3-bornylidenemethyl-10-sulfonic acid
  • Advantageous UV filter substances in the sense of the present invention are also so-called broadband filters, i.e. Filter substances that absorb both UV-A and UV-B radiation.
  • Advantageous broadband filters or UV-B filter substances are, for example, bis-resorcinyltriazine derivatives with the following structure:
  • R 1 , R 2 and R 3 are independently selected from the group of branched and unbranched alkyl groups having 1 to 10 carbon atoms or a single hydrogen atom. Particularly preferred are the 2,4-bis - ⁇ [4- (2-ethylhexyloxy) -2-hydroxy] phenyl ⁇ -6- (4-methoxyphenyl) -1,3,5-triazine (INCI: Aniso triazine ), which is available under the trade name Tinosorb® S from CIBA-Chemicals GmbH.
  • Particularly advantageous preparations in the sense of the present invention which are distinguished by a high or very high UV-A protection, preferably contain a plurality of UV-A and / or broadband filters, in particular dibenzoylmethane derivatives [for example 4- (tert-butyl) -4'-methoxydibenzoylmethane], benzotriazole derivatives [e.g.
  • UV filter substances which the structural motif
  • UV filter substances for the purposes of the present invention, for example the s-triazine derivatives described in European patent application EP 570 838 A1, the chemical structure of which is given by the generic formula
  • R represents a branched or unbranched C ⁇ C ⁇ alkyl radical, a C 5 -C 12 cycloalkyl radical, optionally substituted with one or more C r C 4 alkyl groups
  • X represents an oxygen atom or an NH group
  • R a branched or unbranched CrC ⁇ alkyl, a C 5 -C 12 cycloalkyl, optionally substituted with one or more CC 4 alkyl groups, or a
  • Hydrogen atom an alkali metal atom, an ammonium group or a group of the formula
  • A represents a branched or unbranched C 1 -C 4 -alkyl radical, a C 5 -C 12 -cycloalkyl or aryl radical, optionally substituted by one or more CC 4 -alkyl groups
  • R 3 represents a hydrogen atom or a methyl group
  • n is a number from 1 to 10
  • R 2 represents a branched or unbranched C 1 -C 4 -alkyl radical, a C 5 -C 12 cycloalkyl radical, optionally substituted with one or more dC 4 -alkyl groups, when X represents the NH group, and - " a branched or unbranched CC ⁇ alkyl radical, a C 5 -C 12 cycloalkyl radical, optionally substituted with one or more 0, -0- 4 - alkyl groups, or a hydrogen atom, an alkali metal atom, an ammonium group or a group of the formula
  • A represents a branched or unbranched CC ⁇ alkyl radical, a C 5 -C 12 cycloalkyl or aryl radical, optionally substituted by one or more C, -C 4 alkyl groups
  • R 3 represents a hydrogen atom or a methyl group
  • n is a Represents a number from 1 to 10 when X represents an oxygen atom.
  • a particularly preferred UV filter substance in the sense of the present invention is also an asymmetrically substituted s-triazine, the chemical structure of which is represented by the formula
  • dioctylbutylamidotriazon (INCI: Dictylbutamidotriazone) and is available under the trade name UVASORB HEB from Sigma 3V.
  • a symmetrically substituted s-triazine which is 4,4 ', 4 "- (1,3,5-triazine-2,4,6-triyltriimino) tris-benzoic acid tris (2- ethylhexyl ester), synonym: 2,4,6-tris [anilino- (p-carbo-2'-ethyl-1'-hexyloxy)] - 1,3,5-triazine (INCI: octyl triazone), which is marketed by BASF Aktiengesellschaft under the trade name UVINUL® T 150.
  • R, R 2 and A represent a wide variety of organic radicals.
  • Also advantageous in the sense of the present invention are the 2,4-bis - ⁇ [4- (3-sulfonato) - 2-hydroxypropyloxy) -2-hydroxy] phenyl ⁇ -6- (4-methoxyphenyl) -1, 3,5-triazine sodium salt, the 2,4-bis - ⁇ [4- (3- (2-propyloxy) -2-hydroxypropyloxy) -2-hydroxy] phenyl ⁇ -6- (4-methoxyphenyl ) -1, 3,5-triazine, the 2,4-bis - ⁇ [4- (2-ethylhexyloxy) -2-hydroxy] phenyl ⁇ -6- [4- (2-methoxyethyl carboxyl ) -phenylamino] -1, 3,5-triazine, the 2,4-bis - ⁇ [4- (3- (2-propyloxy) -2-hydroxypropyloxy) -2-hydroxy] phenyl ⁇ -6- [4
  • An advantageous broadband filter for the purposes of the present invention is 2,2'-methylene-bis- (6- (2H-benzotriazol-2-yl) -4- (1,1,3,3-tetramethylbutyl) phenol), which through the chemical structural formula
  • Tinosorb® M is marked and is available under the trade name Tinosorb® M from CIBA Chemical GmbH.
  • Another advantageous broadband filter for the purposes of the present invention is 2- (2H-benzothazol-2-yl) -4-methyl-6- [2-methyl-3- [1, 3,3,3-tetramethyl-1 - [( trimethylsilyl) oxy] di- siloxanyl] propyl] phenol (CAS No .: 155633-54-8) with the INCI name Drometrizole Trisiloxane, which is characterized by the chemical structural formula
  • the UV-B and / or broadband filters can be oil-soluble or water-soluble.
  • Advantageous oil-soluble UV-B and / or broadband filter substances are e.g. B .:
  • 3-benzylidene camphor derivatives preferably 3- (4-methylbenzylidene) camphor, 3-benzylidene camphor;
  • 4-aminobenzoic acid derivatives preferably 4- (dimethylamino) benzoic acid (2-ethylhexyl) ester, 4- (dimethylamino) benzoic acid amyl ester;
  • esters of benzalmalonic acid preferably 4-methoxybenzalmalonic acid di (2-ethylhexyl) ester
  • ⁇ esters of cinnamic acid preferably 4-methoxycinnamic acid (2-ethylhexyl) ester, 4-methoxycinnamic acid isopentyl ester
  • benzophenone preferably 2-hydroxy-4-methoxybenzophenone, 2-hydroxy-4-methoxy-4'-methylbenzophenone, 2,2'-dihydroxy-4-methoxybenzophenone
  • Advantageous water-soluble UV-B and / or broadband filter substances are e.g. B .:
  • a further light protection filter substance to be used advantageously according to the invention is ethylhexyl-2-cyano-3,3-diphenylacrylate (octocrylene), which is available from BASF under the name Uvinul ® N 539 and is characterized by the following structure:
  • the preparations according to the invention advantageously contain the substances which absorb UV radiation in the UV-A : and / or UV-B range in a total amount of, for. B. 0.1 wt .-% to 30 wt .-%, preferably 0.5 to 20 wt .-%, in particular 1, 0 to 15.0 wt .-%, each based on the total weight of the preparations to cosmetic
  • 0.1 wt .-% to 30 wt .-% preferably 0.5 to 20 wt .-%, in particular 1, 0 to 15.0 wt .-%, each based on the total weight of the preparations to cosmetic
  • Emulsion II% by weight% by volume Emulsion II% by weight% by volume
  • Predispersion of the inorganic gel formers and swelling of the hydrocolloid with stirring in the water phase Combination of the fat phase heated to 80 ° C with the water phase heated to 75 ° C. Homogenization using a gear rim dispersing machine (rotor-stator principle) at 65 ° C. 45 min stirring in the Becomix with gassing with nitrous oxide at 0.7 bar with cooling to 30 ° C. Add the additives at 30 ° C (perfume, Active ingredients). Homogenization using a gear rim dispersion machine (rotor-stator principle) at 26 ° C.
  • Vitamin E acetate 2.00
  • Predispersion of the inorganic gelling agent (hectorite) and swelling of the hydrocolloids while stirring in the water phase Predispersion of the Quatemium 18 hectorite in the hot fat phase.
PCT/EP2002/002853 2001-03-15 2002-03-14 Selbstschäumende oder schaumförmige zubereitungen organischer hydrokolloiden WO2002074257A2 (de)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US10/469,698 US20040142006A1 (en) 2001-03-15 2002-03-14 Self-foaming or foamed preparations consisting of organic hydrocolloids
JP2002572968A JP2004519498A (ja) 2001-03-15 2002-03-14 有機ヒドロコロイドから成る自己発泡性または発泡された調製物
EP02726173A EP1370215A2 (de) 2001-03-15 2002-03-14 Selbstschaumende oder schaumformige zubereitungen organische hydrokolloide enthaltend

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10113050.3 2001-03-15
DE10113050A DE10113050A1 (de) 2001-03-15 2001-03-15 Selbstschäumende oder schaumförmige Zubereitungen organischen Hydrokolloiden

Publications (2)

Publication Number Publication Date
WO2002074257A2 true WO2002074257A2 (de) 2002-09-26
WO2002074257A3 WO2002074257A3 (de) 2003-04-10

Family

ID=7677939

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/002853 WO2002074257A2 (de) 2001-03-15 2002-03-14 Selbstschäumende oder schaumförmige zubereitungen organischer hydrokolloiden

Country Status (5)

Country Link
US (1) US20040142006A1 (US20040142006A1-20040722-C00011.png)
EP (1) EP1370215A2 (US20040142006A1-20040722-C00011.png)
JP (1) JP2004519498A (US20040142006A1-20040722-C00011.png)
DE (1) DE10113050A1 (US20040142006A1-20040722-C00011.png)
WO (1) WO2002074257A2 (US20040142006A1-20040722-C00011.png)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE202010011395U1 (de) 2010-08-13 2010-11-11 Beiersdorf Ag Stabilisierte W/O-Emulsionen
WO2012020075A2 (de) 2010-08-13 2012-02-16 Beiersdorf Ag Stabilisierte w/o-emulsionen

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2371362B1 (en) 2004-01-22 2020-07-01 University of Miami Co-enzyme Q10 formulations for treating solid tumours by intravenous administration
DE202005011885U1 (de) * 2005-07-28 2006-08-31 Schwan-Stabilo Cosmetics Gmbh & Co. Kg Geschäumte Zubereitung
EP2136787B1 (en) 2007-03-22 2019-08-21 Berg LLC Topical formulations having enhanced bioavailability
BRPI0911658A2 (pt) 2008-04-11 2015-10-13 Cytotech Labs Llc métodos e usos de indução de apoptose em células de câncer
EP2429512A4 (en) 2009-05-11 2013-07-31 Berg Pharma Llc METHODS FOR TREATING METABOLIC DISORDERS USING EPIMETABOLIC DECALS, MULTIDIMENSIONAL INTRACELLULAR MOLECULES OR ENVIRONMENTAL INFLUENCERS
US11400058B2 (en) 2010-03-12 2022-08-02 Berg Llc Intravenous formulations of coenzyme Q10 (CoQ10) and methods of use thereof
CA2832324C (en) 2011-04-04 2022-03-15 Berg Llc Methods of treating central nervous system tumors
CN107095863A (zh) 2011-06-17 2017-08-29 博格有限责任公司 可吸入药物组合物
SG11201508272YA (en) 2013-04-08 2015-11-27 Berg Llc Treatment of cancer using coenzyme q10 combination therapies
EP3730131A1 (en) 2013-09-04 2020-10-28 Berg LLC Methods of treatment of cancer by continuous infusion of coenzyme q10

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3535454A1 (de) * 1985-10-04 1987-04-09 Bayer Ag Verschaeumbare zubereitungen
US4808388A (en) * 1986-08-20 1989-02-28 Merz + Co. Gmbh & Co. Foamable creams
WO1999008649A2 (de) * 1997-08-18 1999-02-25 Neubourg, Stephanie Schaum-hautschutzcreme
EP0938890A2 (en) * 1997-12-18 1999-09-01 Unilever Plc Cosmetic skin or hair care compositions

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5326556A (en) * 1991-01-25 1994-07-05 The Gillette Company Shaving compositions
DE4224761A1 (de) * 1992-07-27 1994-02-03 Basf Ag Verwendung von Polykondensaten und neue Polykondensate
DE4225045A1 (de) * 1992-07-29 1994-02-03 Basf Ag Verwendung von wasserlöslichen oder in Wasser dispergierbaren Polyurethanen als Hilfsmittel in kosmetischen und pharmazeutischen Zubereitungen und Polyurethane, die Polymilchsäurepolyole einpolymerisiert enthalten
DE4241118A1 (de) * 1992-12-07 1994-06-09 Basf Ag Verwendung von kationischen Polyurethanen und Polyharnstoffen als Hilfsmittel in kosmetischen und pharmazeutischen Zubereitungen
DE4314305A1 (de) * 1993-04-30 1994-11-03 Basf Ag Haarfestigungsmittel
FR2709982B1 (fr) * 1993-09-15 1995-12-08 Oreal Emulsions acides stables de type huile-dans-eau et compositions les contenant.
US5505935A (en) * 1994-05-09 1996-04-09 Elizabeth Arden Company, Division Of Conopco, Inc. Sunscreen compositions
ATE178203T1 (de) * 1994-11-28 1999-04-15 Procter & Gamble Topische hautpflegemittel enthaltend verdickte polyolestern von carbonsaüren als haut konditionierende agentien
FR2732594B1 (fr) * 1995-04-07 1997-06-06 Oreal Utilisation de derives d'acide salicylique pour la depigmentation de la peau
US5720949A (en) * 1996-05-06 1998-02-24 Bristol-Myers Squibb Company Foamable cosmetic mask product
FR2751535B1 (fr) * 1996-07-25 1998-11-27 Oreal Utilisation de derives de la melatonine pour la la depigmentation de la peau et compositions les comprenant
BR9612763A (pt) * 1996-11-04 1999-12-07 Procter & Gamble Composição cosmética para clarear a pele e processos para clarear a pele e preparar essa composição
AU4991497A (en) * 1996-11-12 1998-06-03 Pharmacia & Upjohn Company Pharmaceutical compositions containing kukui nut oil
US5824326A (en) * 1997-06-27 1998-10-20 Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. Activity enhancement of ferulic acid with dimethyl isosorbride in cosmetic compositions
IT1293508B1 (it) * 1997-07-30 1999-03-01 3V Sigma Spa Associazione di filtri solari e composizioni che le contengono
US5968530A (en) * 1997-10-17 1999-10-19 International Flora Technologies, Inc. Emollient compositions
WO1999024003A1 (en) * 1997-11-10 1999-05-20 The Procter & Gamble Company Compositions containing combinations of liquid polyol fatty acid polyesters and a liquid oil
DE19754659C2 (de) * 1997-12-09 2000-09-07 Hans Joachim Schwanitz Verwendung von Kohlensäure zur Stabilisierung oder Erhöhung der epidermalen Ceramidsyntheserate
FR2775897B1 (fr) * 1998-03-13 2000-06-30 Oreal Utilisation d'amidon comme actif destine au traitement et/ou a la prevention de l'apparition des signes du vieillissement dans une composition cosmetique ou dermatologique
FR2789397A1 (fr) * 1999-02-09 2000-08-11 Shiseido International France Compositions cosmetiques a texture legere
KR100781834B1 (ko) * 1999-06-03 2007-12-03 유니레버 엔.브이. 분지형 에스테르를 함유하는 피지 억제용 스킨 케어화장품 조성물
DE19934943B4 (de) * 1999-07-26 2007-08-02 Beiersdorf Ag Kosmetische und dermatologische Zubereitungen auf der Grundlage von O/W-Emulsionen
DE19934945A1 (de) * 1999-07-26 2001-02-01 Beiersdorf Ag Kosmetische und dermatologische Zubereitungen auf der Grundlage von O/W-Emulsionen
DE19934946A1 (de) * 1999-07-26 2001-02-01 Beiersdorf Ag Kosmetische und dermatologische Zubereitungen auf der Grundlage von O/W-Emulsionen
DE19934944A1 (de) * 1999-07-26 2001-02-01 Beiersdorf Ag Kosmetische und dermatologische Zubereitungen auf der Grundlage von O/W-Emulsionen
FR2798078B1 (fr) * 1999-09-06 2001-10-12 Oreal Organogel, comprenant un compose hydrophile sensible a l'oxydation et ses utilisations notamment cosmetiques

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3535454A1 (de) * 1985-10-04 1987-04-09 Bayer Ag Verschaeumbare zubereitungen
US4808388A (en) * 1986-08-20 1989-02-28 Merz + Co. Gmbh & Co. Foamable creams
WO1999008649A2 (de) * 1997-08-18 1999-02-25 Neubourg, Stephanie Schaum-hautschutzcreme
EP0938890A2 (en) * 1997-12-18 1999-09-01 Unilever Plc Cosmetic skin or hair care compositions

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE202010011395U1 (de) 2010-08-13 2010-11-11 Beiersdorf Ag Stabilisierte W/O-Emulsionen
WO2012020075A2 (de) 2010-08-13 2012-02-16 Beiersdorf Ag Stabilisierte w/o-emulsionen

Also Published As

Publication number Publication date
US20040142006A1 (en) 2004-07-22
WO2002074257A3 (de) 2003-04-10
EP1370215A2 (de) 2003-12-17
DE10113050A1 (de) 2002-09-19
JP2004519498A (ja) 2004-07-02

Similar Documents

Publication Publication Date Title
EP1370214B1 (de) Selbstschäumende oder schaumförmige zubereitungen mit anorganischen gelbildnern und organischen hydrokolloiden
EP1377256A2 (de) Selbstschäumende oder schaumförmige zubereitungen mit anorganischen gelbildnern, organischen hydrokolloiden und partikulären hydrophoben und/oder hydrophobisierten und/oder ölabsorbierenden festkörpersubstanzen
WO2002074264A2 (de) Selbstschäumende oder schaumförmige zubereitungen mit organischen hydrokolloiden und partikulären hydrophoben und/oder hydrophobisierten und/oder ölabsorbierenden festkörpersubstanzen
EP1216682A2 (de) Selbstschäumende oder schaumförmige Zubereitungen
EP1411884A2 (de) Schäumbare zubereitungen
DE10144061A1 (de) Selbstschäumende oder schaumförmige Zubereitungen mit anorganischen Gelbildnern, organischen Hydrokolloiden und partikulären hydrophoben und/oder hydrophobisierten und/oder ölabsorbierenden Festkörpersubstanzen
EP1372577A1 (de) Selbstschäumende oder schaumförmige zubereitungen mit partikulären hydrophoben und/oder hydrophobisierten und/oder ölabsorbierenden festkörpersubstanzen
WO2002074257A2 (de) Selbstschäumende oder schaumförmige zubereitungen organischer hydrokolloiden
EP1216684A1 (de) Selbstschäumende oder schaumförmige Zubereitungen eine Lipidphase enthaltend
EP1372576B1 (de) Selbstschäumende oder schaumförmige zubereitungen mit anorganischen gelbildnern und partikularen festkörpersubstanzen
EP1216683A1 (de) Selbstschäumende oder schaumförmige Zubereitungen eine Lipidphase enthaltend
EP1410783B1 (de) Schäumbare Zubereitungen
EP1352641A2 (de) Selbstschäumende oder schaumförmige Zubereitungen, enthaltend ein oder mehrere vorgelatinisierte, quervernetzte Stärkederivate
EP1411883A2 (de) Schäumbare zubereitungen
EP1370216A2 (de) Selbstschäumende oder schaumförmige zubereitungen mit anorganischen gelbildnern

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2002726173

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2002572968

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2002726173

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10469698

Country of ref document: US

WWW Wipo information: withdrawn in national office

Ref document number: 2002726173

Country of ref document: EP